XTL Biopharmaceuticals (FRA:H2K2) Total Equity : €2.49 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is XTL Biopharmaceuticals Total Equity?

XTL Biopharmaceuticals's total equity for the quarter that ended in Mar. 2024 was €2.49 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

XTL Biopharmaceuticals Total Equity Historical Data

The historical data trend for XTL Biopharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XTL Biopharmaceuticals Total Equity Chart

XTL Biopharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Equity

Get a 7-Day Free Trial

5.86

2.97

4.72

3.78

2.04

XTL Biopharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Equity	Get a 7-Day Free Trial															2.88	2.51	2.34	2.04	2.49

XTL Biopharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

XTL Biopharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	2.225	-	0.189
	=	2.04

XTL Biopharmaceuticals's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity	=	Total Assets(Q: Mar. 2024 )	-	Total Liabilities(Q: Mar. 2024 )
	=	2.694	-	0.205
	=	2.49

XTL Biopharmaceuticals Total Equity Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

XTL Biopharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (FRA:H2K2) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

XTLB:USA XTLB:Israel

Address

26 Ben-Gurion Street, Ramat Gan, ISR, 5112001

Website

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

XTL Biopharmaceuticals Headlines

No Headlines